Betadex Sulfobutyl Ether Sodium Salt

Description:
Sulfobutylether b-cyclodextrin is an anionic bcyclodextrin derivative with a
sodium sulfonate salt separated from the hydrophobic cavity by a butyl
spacer group. The substituent is introduced at positions 2, 3, and 6 in at
least one of the glucopyranose units in the cyclodextrin structure.
Introducing the sulfobutylether (SBE) into b-cyclodextrin can produce
materials with different degrees of substitution, theoretically from 1 to
21; the hepta-substituted preparation (SBE7-b-CD) is the cyclodextrin with
the most desirable drug carrier properties. Sulfobutylether b-cyclodextrin
occurs as a white amorphous powder.
Betadex Sulfobutyl Ether Sodium salt is an excipient mainly used in
nitrogen-containing drugs. It has special affinity and inclusion properties
for nitrogen-containing drugs.
Characteristics & Applications:
SBE- β –CD is a chemically modified cyclodextrin with a structure designed
to optimize the solubility and stability of drugs.The amount of
sulfobutylether β-cyclodextrin that may be used is dependent on the purpose
for inclusion in the formulation, the route of administration, and the
ability of the cyclodextrin to complex with the drug being delivered.
Betadex Sulfobutyl Ether Sodium salt is the sulfonated modified sodium salt
of beta cyclodextrin,which is an anionic, highly water-soluble cyclodextrin
derivative, can be well incorporated with drug molecules to form non-
covalent complexes, thereby improving the stability, water solubility and
safety of the drug , reducing nephrotoxicity, ease drug hemolysis, control
drug release rate, mask bad odor, etc.
Zhiyuan Biotechnology ulfobutylether b-cyclodextrin is derived from b-
cyclodextrin, which is nephrotoxic when administered parenterally. However,
studies have shown that sulfobutylether bcyclodextrin is well tolerated at
high doses, when administered via intravenous bolus injections, orally, and
by inhalation. Up to 9 g/day may be administered by IV infusion in a
licensed voriconazole formulation. The safety following high doses of
sulfobutylether β-cyclodextrin intravenous administration in humans is
continually being investigated.
Sulfobutylether β-cyclodextrin has been subjected to an extensive battery
of in vitro and in vivo genotoxicity and pharmacological evaluations. No
genotoxic or mutagenic changes were observed with sulfobutylether β-
cyclodextrin administration. High purity Sulfobutylether β-cyclodextrin is
biocompatible and exhibits no pharmacological activity. It is rapidly
eliminated unmetabolized when administered intravenously.

Click to Enlarge